Emergent BioSolutions IND for Anthrax Monoclonal Antibody Therapeutic Clears FDA Review
Emergent BioSolutions Inc. (NYSE:EBS) announced today that its Investigational New Drug (IND) application, to commence a Phase I clinical trial for its anthrax monoclonal antibody therapeutic, has...
Emergent BioSolutions Recognized as Biotechnology Firm of the Year by Tech Council of Maryland
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has been named Biotechnology Firm of the Year at the Tech Council of Maryland's (TCM) Annual Tech Awards. This award acknowledges the...
Emergent BioSolutions Hosts Biopreparedness Forum for Members of the NATO Parliamentary Assembly
Emergent BioSolutions Inc. (NYSE:EBS) is hosting "Bioterrorism Prevention, Preparedness and Response," a forum uniquely organized for members of the North Atlantic Treaty Organization (NATO)...
Emergent BioSolutions Reports Financial Results for First Quarter 2010
Emergent BioSolutions Inc. (NYSE: EBS) announced today its financial results for the first quarter ended March 31, 2010. For the first quarter 2010, total revenues were $46.8 million as compared to...
Emergent BioSolutions to Participate on Vaccine Panel at BIO International Convention 2010
Emergent BioSolutions Inc. (NYSE:EBS) announced today that W. James Jackson, Ph.D., the Company's senior vice president and chief scientific officer, will speak on a panel titled "Vaccines for the...
Emergent BioSolutions to Release First Quarter 2010 Financial Results and Conduct a Conference Call on May 5, 2010
Emergent BioSolutions Inc. (NYSE:EBS) announced today it will report financial results for first quarter 2010 on Wednesday, May 5, 2010, after market close. Company management will host a conference...
Emergent BioSolutions Chairman and CEO Fuad El-Hibri Recognized as Outstanding International Business Leader
Emergent BioSolutions Inc. (NYSE:EBS) announced today that Fuad El-Hibri, its chairman and chief executive officer, has been named by the World Trade Center Institute (WTCI) as one of Maryland's...
Emergent BioSolutions Reports Financial Results for Full Year 2009
2009 record revenues of $234.8 million 2009 net income of $31.1 million, or $1.02 per share, representing eighth consecutive year of profitability 2009 cash and accounts receivable balance of...
Emergent BioSolutions to Participate in March 2010 Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will be participating in the following investor conferences during March...
Emergent BioSolutions to Release Fourth Quarter and Full Year 2009 Financial Results and Conduct a Conference Call on March 4, 2010
Emergent BioSolutions Inc. (NYSE: EBS) announced today it will report financial results for fourth quarter and full year 2009 on Thursday, March 4, 2010, after market close. Company management will...
Emergent BioSolutions Provides Preliminary 2009 Financial Results and Guidance for 2010
Anticipated for 2009: Record Revenue of $234 Million; Net Income of $25 to $28 Million; and Yearend Cash Balance in Excess of $100 MillionForecasted for 2010: Total Revenue of $235 to $255 Million...
Emergent BioSolutions Announces R. Don Elsey, Chief Financial Officer, to Join Board of Directors of MdBio Foundation
Emergent BioSolutions Inc. (NYSE:EBS) announced today that R. Don Elsey, chief financial officer (CFO) and senior vice president of finance and administration, has joined the board of directors of...